Equibles does not estimate personal net worth.
Earlier roles on record: Chairman at Geron Corp (GERN) until March 10, 2025 and Board Member at CytomX Therapeutics, Inc. (CTMX) until June 15, 2022. The proxy statement of Geron Corp reports total compensation of $7,422,754 for John Scarlett in fiscal 2025, including a base salary of $309,781. Disclosed compensation is on record for 9 fiscal years. John Scarlett has spoken on 15 earnings calls across 1 company, most recently for Geron Corp on January 13, 2025. The companies whose calls John Scarlett spoke on are classified in the Healthcare sector.
“2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor. RYTELO has a unique mechanism of action that represents a highly differentiated treatment with blockbuster potential in this high unmet need lower-risk MDS population.”
“Following FDA approval and the commercial launch of RYTELO, our first-in-class telomerase inhibitor, this has been a transformative year for Geron. As a result, we believe we're well-positioned to build long-term commercial value with this product.”
“We're poised for a successful U.S. launch of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS. If approved, we're deeply excited for the opportunity to bring patients what we believe is an important and differentiated medicine.”
“Geron's progress and execution throughout 2023 has paved the way for a potentially transformational 2024 as we plan for the transition to becoming a commercial company.”
“This quarter, we continue to make important progress and build momentum along our planned path to develop and commercialize imetelstat, our first-in-class telomerase inhibitor.”
Start not stated–2025-03-10
Start not stated–2022-06-15
GERN
Biotechnology · Healthcare
Chairman
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Geron Corp (GERN) | Former Chairman of the Board, President and Chief Executive Officer | $309,781 | $7,422,754 |
| 2024 | Geron Corp (GERN) | Former Chairman of the Board, President and Chief Executive Officer | $810,600 | $6,125,238 |
| 2023 | Geron Corp (GERN) | Former Chairman of the Board, President and Chief Executive Officer | $787,000 | $4,924,092 |
| 2022 | Geron Corp (GERN) | Former Chairman of the Board, President and Chief Executive Officer | $761,320 | $2,997,202 |
| 2021 | Geron Corp (GERN) | Chairman of the Board, President and Chief Executive Officer | $735,575 | $2,056,987 |
| 2020 | Geron Corp (GERN) | Chairman of the Board, President and Chief Executive Officer | $714,150 | $1,876,209 |
| 2019 | Geron Corp (GERN) | Chairman of the Board, President and Chief Executive Officer | $690,000 | $1,941,135 |
| 2018 | Geron Corp (GERN) | Chairman of the Board, President and Chief Executive Officer | $667,000 | $2,772,509 |
| 2017 | Geron Corp (GERN) | Chairman of the Board, President and Chief Executive Officer | $644,000 | $2,719,310 |
